1. Home
  2. LITB vs SCYX Comparison

LITB vs SCYX Comparison

Compare LITB & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LITB
  • SCYX
  • Stock Information
  • Founded
  • LITB 2007
  • SCYX 1999
  • Country
  • LITB Singapore
  • SCYX United States
  • Employees
  • LITB N/A
  • SCYX N/A
  • Industry
  • LITB Catalog/Specialty Distribution
  • SCYX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LITB Consumer Discretionary
  • SCYX Health Care
  • Exchange
  • LITB Nasdaq
  • SCYX Nasdaq
  • Market Cap
  • LITB 36.4M
  • SCYX 32.3M
  • IPO Year
  • LITB N/A
  • SCYX 2014
  • Fundamental
  • Price
  • LITB N/A
  • SCYX $0.78
  • Analyst Decision
  • LITB
  • SCYX
  • Analyst Count
  • LITB 0
  • SCYX 0
  • Target Price
  • LITB N/A
  • SCYX N/A
  • AVG Volume (30 Days)
  • LITB 32.6K
  • SCYX 553.8K
  • Earning Date
  • LITB 09-09-2025
  • SCYX 11-05-2025
  • Dividend Yield
  • LITB N/A
  • SCYX N/A
  • EPS Growth
  • LITB N/A
  • SCYX N/A
  • EPS
  • LITB 0.12
  • SCYX N/A
  • Revenue
  • LITB $220,656,000.00
  • SCYX $3,257,000.00
  • Revenue This Year
  • LITB N/A
  • SCYX $422.61
  • Revenue Next Year
  • LITB N/A
  • SCYX $240.56
  • P/E Ratio
  • LITB $16.51
  • SCYX N/A
  • Revenue Growth
  • LITB N/A
  • SCYX N/A
  • 52 Week Low
  • LITB $0.91
  • SCYX $0.66
  • 52 Week High
  • LITB $2.80
  • SCYX $1.62
  • Technical
  • Relative Strength Index (RSI)
  • LITB 55.83
  • SCYX 35.38
  • Support Level
  • LITB $1.93
  • SCYX $0.76
  • Resistance Level
  • LITB $2.06
  • SCYX $1.14
  • Average True Range (ATR)
  • LITB 0.13
  • SCYX 0.07
  • MACD
  • LITB -0.03
  • SCYX -0.04
  • Stochastic Oscillator
  • LITB 21.21
  • SCYX 7.29

About LITB LightInTheBox Holding Co. Ltd.

LightInTheBox Holding Co Ltd is an online retail company delivering products directly to consumers across the world. It provides apparel products including customized, special occasion and fast fashion apparel products; and other general merchandise products, such as accessories and gadgets, home and garden products, electronics and communication devices, and other products. The company operates in two segments: Product sales which consisted of online retailing of consumer products and sales to third-party sellers, and Services which consisted of provision of logistic services to companies and to individual customers. It derives maximum revenue from Product Sales. Geographically, it operates in Europe which is the key revenue driver, North America, and other countries.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: